


In the Claims

1. (Previously presented) A serine protease inhibitor having the formula (I),



in which

J is H, R¹, R¹-O-C(O)-, R¹-C(O)-, R¹-SO₂-, R³OOC-(CHR²)_p-, (R^{2a}, R^{2b})N-CO-(CHR²)_p- or Het-CO-(CHR²)_p-;

Z is an amino-acid of the formula -NH-CHR¹-C(O)-,

-NR⁴-CH((CH₂)_qC(O)OR¹)-C(O)-,


-NR⁴-CH((CH₂)_qC(O)N(R^{2a}, R^{2b}))-C(O)-,

-NR⁴-CH((CH₂)_qC(O)Het)-C(O)-,

D-1-Tiq, D-3-Tiq, D-Atc, Aic, D-1-Piq, D-3

Piq, glutanyl or a (C₁-C₆) alkylester thereof;

E is -NR²-CH₂- or the fragment



, which is unsubstituted or substituted

with (1-6C)alkyl, (1-6C)alkoxy or benzyloxy;

R¹ is selected from (1-12C)alkyl,

(2-12C)alkenyl, (2-12C)alkynyl, (3-12C)cycloalkyl and (3-12C)cycloalkyl(1-6C)alkylene, which groups are

unsubstituted or substituted with (3-12C)cycloalkyl, (1-6C)alkoxy, oxo, OH, CF₃ or halogen, and from

(6-14C)aryl, (7-15C)aralkyl, (8-16C)aralkenyl and

(14-20C)(bisary)alkyl, wherein the aryl groups are

unsubstituted or substituted with (1-6C)alkyl,

(3-12C)cycloalkyl, (1-6C)alkoxy, OH, CF₃ or halogen;

R², R^{2a} and R^{2b} are each independently selected from

H, (1-8C)alkyl, (3-8C)alkenyl, (3-8C)alkynyl,

(3-8C)cycloalkyl and (3-6C)cycloalkyl(1-4C)alkylene, which are unsubstituted or substituted with

Attorney Docket Number O 98411 US

(3-6C)cycloalkyl, (1-6C)alkoxy, CF_3 or halogen, and from (6-14C)aryl and (7-15C)aralkyl, wherein the aryl groups are unsubstituted or substituted with (1-6C)alkyl, (3-6C)cycloalkyl, (1-6C)alkoxy, CF_3 or halogen;

R^3 is the same as R^2 or is Het-(1-6C)alkyl;

R^4 is H or (1-3C)alkyl;

X and Y are CH or N, with the proviso that they are not both N;

Het is a 4-, 5- or 6-membered heterocycle containing

one or more heteroatoms selected from O, N and S;

m is 1 or 2;

p is 1, 2 or 3;

q is 1, 2 or 3;

t is 2, 3 or 4;

or a pharmaceutically acceptable addition salt or solvate thereof.

2. (Previously presented) The serine protease inhibitor according to claim 1, wherein m is 2; X is CH and Y is CH.

3. (Previously presented) The serine protease inhibitor according to claim 2, wherein


J is H, $\text{R}^1 \text{R}^1\text{-SO}_2\text{-}$, $\text{R}^3\text{OOC-(CHR}^2\text{)}_p\text{-}$,
 $(\text{R}^{2a}, \text{R}^{2b})\text{N-CO-(CHR}^2\text{)}_p\text{-}$ or $\text{Het-CO(CHR}^2\text{)}_p\text{-}$;

Z is an amino-acid of the formula $\text{-NH-CHR}^1\text{-C(O)-}$,

$\text{-NR}^4\text{-CH((CH}_2\text{)}_q\text{C(O)OR}^1\text{)-C(O)-}$,

$\text{-NR}^4\text{-CH((CH}_2\text{)}_q\text{C(O)N(R}^{2a}, \text{R}^{2b})\text{)-C(O)-}$,

E is $\text{-N(3-6C)cycloalkyl-CH}_2\text{-}$ or the fragment



, which is unsubstituted or substituted with (1-6C)alkyl or 1-6C)alkoxy;

R^1 is selected from (1-12C)alkyl, (3-12C)cycloalkyl and

Attorney Docket Number O 98411 US

(3-12C)cycloalkyl(1-6C)alkylene, which groups are unsubstituted or substituted with (3-12C)cycloalkyl, (1-6C)alkoxy or oxo, and from (6-14C)aryl, (7-15C)aralkyl and (14-20C)(bisaryl)alkyl, wherein the aryl groups are unsubstituted or substituted with (1-6C)alkyl, (3-12C)cycloalkyl, (1-6C)alkoxy, OH, CF₃ or halogen;

R² is H;

R^{2a} and R^{2b} are each independently selected from H, (1-8C)alkyl, (3-8C)cycloalkyl and (3-6C)cycloalkyl(1-4C)alkylene, which are unsubstituted or substituted with (3-6C)cycloalkyl or (1-6C)alkoxy and from (6-14C)aryl and (7-15C)aralkyl, wherein the aryl groups are unsubstituted or substituted with (1-6C)alkyl, (3-6C)cycloalkyl, (1-6C)alkoxy, CF₃ or halogen;

R³ is selected from H, (1-8C)alkyl, (3-8C)cycloalkyl and (3-6C)cycloalkyl(1-4C)alkylene, which are unsubstituted or substituted with (3-6C)cycloalkyl or (1-6C)alkoxy, and from (7-15C)aralkyl, wherein the aryl groups are unsubstituted or substituted with (1-6C)alkyl, (3-6C)cycloalkyl, (1-6C)alkoxy, CF₃ or halogen and from Het-(1-6C)alkyl;

p is 1;

q is 2;

t is 3 or 4.

4. (Previously presented) The serine protease inhibitor according to claim 3, wherein

Z is an amino-acid of the formula -NH-CHR¹-C(O)- or glutamyl or an (1-6C)alkylester thereof;

R¹ is selected from (3-12C)cycloalkyl and (3-12C)cycloalkyl(1-6C)alkylene, which groups are unsubstituted or substituted with (3-12C)cycloalkyl or (1-6C)alkoxy, and from (6-14C)aryl, (7-15C)aralkyl and (14-20C)(bisaryl)alkyl, wherein the